News & Videos - GENMAB A/S GNMSF - Page 5

Media Release Copenhagen, Denmark, January 6, 2021 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 39 th Annual J.P. Morgan Healthcare Conference at 10:00 AM EST / 4.00 PM CET on January 13, 2021. The live and archived webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content . About Genmab Genmab is an international biotechnology company with a core purpose...

Company Announcement Copenhagen, Denmark; January 5, 2021 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the...

Media Release COPENHAGEN, Denmark, Jan. 04, 2021 Initiation of a global phase 3 trial for tisotumab vedotin versus investigator’s choice chemotherapy in recurrent or metastatic cervical cancer Genmab A/S (Nasdaq: GMAB) announced today the initiation of innovaTV 301 trial, a global phase 3 study to evaluate the efficacy of tisotumab vedotin compared to chemotherapy in patients with recurrent or metastatic cervical cancer who have received one or two prior lines of systemic therapy. The innovaTV...

Company Announcement Copenhagen, Denmark; December 15, 2020 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by...

Company Announcement Copenhagen, Denmark; December 15, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 9,663 restricted stock units to members of the board of directors and employees of the company as well as the company's subsidiaries and 24,964 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab...

Media Release Copenhagen, Denmark, December 3, 2020 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations First regulatory submission for a DuoBody ® product candidate Genmab A/S (Nasdaq: GMAB) announced today that Janssen Biotech, Inc. (Janssen) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) seeking approval of amivantamab for the...

Company Announcement Genmab will not advance the development of enapotamab vedotin Data from expansion cohorts did not meet stringent criteria for proof-of-concept Genmab to prioritize development of other innovative product candidates Copenhagen, Denmark; November 24, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that it will not advance the development of enapotamab vedotin. While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose...

Company Announcement Copenhagen, Denmark; November 10, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,402 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 750 shares at DKK 31.75, 28,600 shares at DKK 40.41, 3,750 shares at DKK 55.85, 137 shares at DKK 337.40,...

Media Release Copenhagen, Denmark, November 10, 2020 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. and CFO Anthony Pagano, will present an update at the Jefferies Virtual London Healthcare Conference at 09.40 AM EST / 03.40 PM CET on November 17, 2020 . A webcast of the event will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content About Genmab Genmab is a publicly traded, international biotechnology company specializing...

Company Announcement First Phase 3 study of epcoritamab as part of broad clinical development plan with AbbVie Diffuse Large B-cell Lymphoma is the most common form of non-Hodgkin’s lymphoma worldwide Copenhagen, Denmark; November 5, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that it will initiate a Phase 3 study of epcoritamab in diffuse large B-cell lymphoma (DLBCL). The study will evaluate the efficacy and safety of subcutaneous epcoritamab, a fully-human IgG1-bispecific antibody...

Media Release Copenhagen, Denmark, November 5, 2020 Janssen submitted a Type II variation application to the European Medicines Agency for subcutaneous formulation of daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone in light-chain (AL) amyloidosis Submission is based on data from the Phase 3 ANDROMEDA (AMY3001) study Genmab A/S (Nasdaq: GMAB) announced today that Janssen Pharmaceutica NV (Janssen) has submitted a Type II variation application to the European...

November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020 Highlights Novartis granted U.S. FDA approval for Kesimpta ® (ofatumumab) in relapsing multiple sclerosis Janssen and European Myeloma Network achieved positive topline results from Phase 3 APOLLO study of daratumumab in relapsed or refractory multiple myeloma Janssen was granted U.S. FDA approval for DARZALEX ® (daratumumab) in combination with carfilzomib and dexamethasone in relapsed or...

Media Release Copenhagen, Denmark, November 4, 2020 More than 40 abstracts on Genmab owned and partnered programs scheduled for presentation at ASH Data from ongoing Phase I/II epcoritamab trial accepted for oral presentation Daratumumab featured in five oral presentations with a total of 37 accepted abstracts, including ISS (Investigator Sponsored Studies) and Market Access abstracts Genmab to host virtual 2020 ASH data review meeting December 8 Genmab A/S (Nasdaq: GMAB) announced today that...

Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020 ADC Therapeutics to continue the development and commercialization of Cami Genmab to receive mid-to-high single-digit tiered royalty Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreement for ADC Therapeutics to continue the development and commercialization of camidanlumab tesirine (Cami). The parties first entered into a collaboration and license...

Company Announcement Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free survival at a pre-planned interim analysis Independent Data Monitoring Committee recommends unblinding the study results Based on the data, Janssen plans to discuss the potential for a regulatory submission with health authorities Copenhagen, Denmark;...

Media Release Copenhagen, Denmark, October 15, 2020 Genmab will host Capital Markets Day November 13, 2020 Highlights to be covered will include an overview of our pipeline with focus on epcoritamab, tisotumab vedotin and DuoBody ® -PD-L1x4-1BB, our DuoBody ® technology platform, and insights into our growing capabilities across Genmab Genmab A/S (Nasdaq: GMAB) announced today that it will hold a Capital Markets Day for analysts and investors on November 13, 2020 from 8:30 AM EST / 2:30 PM CET...

Media Release Copenhagen, Denmark, October 14, 2020 Preliminary data from Phase 1/2a trial of DuoBody ® -PD-L1x4-1BB (GEN1046) in patients with advanced solid tumors accepted for e-poster presentation Pre-clinical data for DuoBody-PD-L1x4-1BB (GEN1046), tisotumab vedotin and DuoBody-CD3x5T4 will also be presented Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts for Genmab programs were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 35th...

Company Announcement Net sales of DARZALEX ® in the third quarter of 2020 totaled USD 1,099 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 13, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous formulation (sold under the tradename DARZALEX FASPRO TM in the U.S.), as reported by Johnson & Johnson were USD 1,099 million in the third...

Company Announcement Copenhagen, Denmark; October 7, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 14,187 restricted stock units and 43,941 warrants to employees of the company and three of the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing...

Company Announcement Copenhagen, Denmark; September 30, 2020 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by...